Roivant Sciences Ltd.
ROIV
71 insider filings · Latest: Oct 1, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Aug 18 8:29 PM | MAYUKH SUKHATME | Proposed Sale | 136,942 | $36.73 | $5.0M | — | View → |
| Aug 17, 2026 | Aug 17 8:40 PM | MAYUKH SUKHATME | Proposed Sale | 284,707 | $36.25 | $10.3M | — | View → |
| Aug 14, 2026 | Aug 14 8:20 PM | MAYUKH SUKHATME | Proposed Sale | 243,177 | $36.23 | $8.8M | — | View → |
| Jul 27, 2026 | Jul 30 1:00 AM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $34.95 | $7.0M | 1,613,063(D) | View → |
| Jul 27, 2026 | Jul 27 8:16 PM | Venker Eric | Proposed Sale | 200,000 | $34.95 | $7.0M | — | View → |
| Jun 30, 2026 | Jul 2 11:03 PM | Meghan FitzgeraldDirector | Sale | 10,000 | $34.90 | $349.0K | 42,963(D) | View → |
| Jun 29, 2026 | Jul 1 10:34 PM | Melissa B, EpperlyDirector | Sale | 17,750 | $34.38 | $610.3K | 16,474(D) | View → |
| Jun 30, 2026 | Jul 1 12:38 AM | Keith S ManchesterDirector | Sale | 212,380 | $35.44 | $7.5M | 1,748,403(I) | View → |
| Jun 29, 2026 | Jul 1 12:38 AM | Keith S ManchesterDirector | Sale | 800,000 | $34.55 | $27.6M | 13,701,546(I) | View → |
| Jun 26, 2026 | Jul 1 12:38 AM | Keith S ManchesterDirector | Sale | 625,783 | $34.00 | $21.3M | 14,501,546(I) | View → |
| Jun 30, 2026 | Jul 1 12:30 AM | Daniel Allen GoldDirector | Sale | 12,380 | $35.28 | $436.8K | 13,689,166(I) | View → |
| Jun 29, 2026 | Jul 1 12:30 AM | Daniel Allen GoldDirector | Sale | 800,000 | $34.55 | $27.6M | 13,701,546(I) | View → |
| Jun 26, 2026 | Jul 1 12:30 AM | Daniel Allen GoldDirector | Sale | 625,783 | $34.00 | $21.3M | 14,501,546(I) | View → |
| Jun 30, 2026 | Jun 30 11:59 PM | QVT Financial LPOther | Sale | 12,380 | $35.28 | $436.8K | 13,689,166(I) | View → |
| Jun 29, 2026 | Jun 30 11:59 PM | QVT Financial LPOther | Sale | 800,000 | $34.55 | $27.6M | 13,701,546(I) | View → |
| Jun 26, 2026 | Jun 30 11:59 PM | QVT Financial LPOther | Sale | 625,783 | $34.00 | $21.3M | 14,501,546(I) | View → |
| Jun 30, 2026 | Jun 30 8:36 PM | MEGHAN FITZGERALD | Proposed Sale | 10,000 | $34.73 | $347.3K | — | View → |
| Jun 30, 2026 | Jun 30 8:25 PM | KEITH S MANCHESTER | Proposed Sale | 200,000 | $35.45 | $7.1M | — | View → |
| Jun 26, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Sale | 500,000 | $34.08 | $17.0M | 18,677,617(D) | View → |
| Jun 25, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Sale | 500,000 | $34.13 | $17.1M | 18,677,617(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,724,363(D) | View → |
| Jun 24, 2026 | Jun 26 10:13 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,244,834(D) | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,444,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,644,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Richard PulikCFO | Grant/Award | 84,026 | $29.08 | 84,026(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Jennifer HumesChief Accounting Officer | Grant/Award | 27,157 | $29.08 | 27,157(D) | View → |
| Mar 30, 2026 | Apr 1 11:20 PM | Matthew GlineDirector, CEO | Option Exercise | 2,178,150 | — | 0(D) | View → |
| Mar 30, 2026 | Apr 1 11:19 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 1,306,889 | — | 0(D) | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Option Exercise | 70,000 | $8.80 | 48,578(D) | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,844,834(D) | View → |
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 587,390 | $3.85 | 3,026,184(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,012,610 | $3.85 | 3,613,574(D) | View → |
| Feb 19, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,400,000 | $3.85 | 4,626,184(D) | View → |
| Feb 13, 2026 | Feb 18 10:57 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 5,044,834(D) | View → |
| Feb 9, 2026 | Feb 11 10:53 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 651,558 | $12.68 | 0(D) | View → |
← Previous
Page 2 of 2